行情

CLRB

CLRB

Cellectar
NASDAQ

实时行情|Nasdaq Last Sale

1.200
+0.100
+9.09%
交易中 14:04 11/19 EST
开盘
1.100
昨收
1.100
最高
1.200
最低
1.100
成交量
5.85万
成交额
--
52周最高
3.750
52周最低
1.040
市值
1,126.40万
市盈率(TTM)
-0.5077
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLRB 新闻

  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.4天前
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.6天前
  • Cellectar Biosciences EPS misses by $0.04
  • seekingalpha.11/12 18:10
  • Cellectar Biosciences Q3 EPS $(0.42) Up From $(1.65) YoY
  • Benzinga.11/12 14:07

更多

所属板块

制药
+0.37%
制药与医学研究
+0.74%

热门股票

名称
价格
涨跌幅

CLRB 简况

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
展开

Webull提供Cellectar Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。